CTLA4 and breast cancer: The association of risk scores with the expression of key immune checkpoint genes (including PD-L1 (CD247), PD1 (PDCD1), LAG3, and CTLA4) were explored and significant negative correlation were found, indicating that BC patients with high-risk scores responded poorly to immune checkpoint blockade therapy (Supplementary Figure 6).